droxidopa 100 mg

1 INDICATIONS AND USAGE Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. Droxidopa Capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa capsules should be assessed periodically ( 1 ).

ScieGen Pharmaceuticals Inc

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] fatigue` `[4] diarrhoea` `[5] pain` `[6] dyspnoea` `[7] headache` `[8] vomiting` `[9] off label use` `[10] dizziness`

2 years ago

CAPSULE BLUE SG 429

16.1 How Supplied

DROXIDOPA capsules are supplied in the following dosage strengths: 100 mg: Off white to light brownish powder filled in size “3” hard gelatin capsules with opaque light blue colored cap and opaque white colored body imprinted ‘SG’ on cap and ‘429’ on body with black ink. Bottles of 30 NDC 50228-429-30 Bottles of 90 NDC 50228-429-90 Bottles of 1,000 NDC 50228-429-10 200 mg: Off white to light brownish powder filled in size “2” hard gelatin capsules with opaque light yellow colored cap and opaque white colored body imprinted ‘SG’ on cap and ‘430’ on body with black ink. Bottles of 30 NDC 50228-430-30 Bottles of 90 NDC 50228-430-90 Bottles of 1,000 NDC 50228-430-10 300 mg: Off white to light brownish powder filled in size “1” hard gelatin capsules with opaque light green colored cap and opaque white colored body imprinted ‘SG’ on cap and ‘431’ on body with black ink. Bottles of 30 NDC 50228-431-30 Bottles of 90 NDC 50228-431-90 Bottles of 500 NDC 50228-431-05

More pills like CAPSULE SG 429

Related Pills

droxidopa 300 mg

ScieGen Pharmaceuticals Inc

droxidopa 200 mg

ScieGen Pharmaceuticals Inc

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

droxidopa 100 mg

FDA Reported Adverse Reactions [1] drug ineffective [2] nausea [3] fatigue [4] diarrhoea [5] pain [6] dyspnoea [7] headache [8] vomiting [9] off label use [10] dizziness

CAPSULE BLUE SG 429

More pills like CAPSULE SG 429

Related Pills

droxidopa 300 mg

droxidopa 200 mg

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] fatigue` `[4] diarrhoea` `[5] pain` `[6] dyspnoea` `[7] headache` `[8] vomiting` `[9] off label use` `[10] dizziness`